Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Expensive Performer
19783.0000 207.00 (1.06%)
NSE Nov 05, 2026 15:31 PM
Volume: 65,552
 

19783.00
1.06%

Neuland Laboratories Ltd Q2FY17 Result Review

BOB Capital Markets Ltd.
Amalgamation Scheme: The scheme involves issue of fresh equity shares by NLL to NHSPL and NPRPL which would increase NLL's equity by 25.6%. Promoter holding would change from 51.68% to 41.29 % post-merger. This would likely come into effect from Q2FY18. The amalgamation is aimed at building stronger business and financials, obtain tax benefits by clubbing R&D; services required for CMS business & better operational convenience. Going forward, we expect NLL to enjoy high margins led by strong...
Promoters pledged 0.03% of shares in last quarter. Total pledge stands at 2.32% of promoter holdings
More from Neuland Laboratories Ltd.
Recommended